Insider Brief
- Conceivable Life Sciences raised a $50M Series A (total funding $70M) to commercialize AURA, an AI-powered automated IVF lab that standardizes more than 200 steps to improve pregnancy outcomes.
- The round was led by Advance Venture Partners with ARTIS Ventures, Stride, and ACME participating, funding a U.S. debut next year and expanded fertility-network partnerships in 2026.
- The company is in active clinical operations with a 100-patient pilot and reports 18 healthy babies from earlier prototypes, aiming to reduce IVF variability while easing capacity and cost/access constraints.
PRESS RELEASE – Conceivable Life Sciences today announced its $50 million Series A financing to accelerate the development and commercialization of the world’s first AI-powered automated IVF laboratory. The funding will support the company’s mission to make this Nobel Prize-winning therapy more accessible, scalable, and effective at delivering improved pregnancy results.
The Series A round was led by Advance Venture Partners (AVP) with participation from existing investors including ARTIS Ventures, Stride, and ACME. This round brings Conceivable’s total funding to $70 million, including the company’s $20 million seed round, which closed in December 2022.
Transforming IVF Through AI and Automation
For decades, IVF labs have depended on manual, artisanal processes that introduce tremendous variability and lead to inconsistent outcomes for infertile patients undergoing IVF treatment. At its core, IVF involves delicate single-cell surgery where sperm and egg are combined to create an embryo—yet this critical work is largely performed with human hands and eyes. Conceivable is revolutionizing IVF through its proprietary automated IVF lab platform: AURA. This brings robotic precision and AI algorithmic exactitude to remove variability and standardize the more than 200 intricate steps with the aim to deliver consistently successful IVF outcomes.
“This funding validates our vision of transforming IVF through AI-powered robotic automation,” said Alan Murray, co-founder and CEO of Conceivable. “Our platform addresses the core challenges facing fertility clinics today —unpredictable success rates, capacity constraints, and accessibility barriers. This investment allows us to accelerate our bringing this groundbreaking technology to market.”
Conceivable is in active clinical operations and currently conducting a 100-patient pilot study. “Ongoing pregnancy results from the current trial are quite positive and we have 18 healthy babies from an earlier study on prototype instruments,” said Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Medical Officer of Conceivable. “Early indications from clinical KPIs are very promising and demonstrate that robotic precision and AI-driven protocols will outperform traditional manual approaches. We are committed to delivering consistent outcomes that fertility patients deserve.”
Strategic Use of Capital
The Series A funding will support Conceivable Life Sciences’s U.S. debut next year, expanding its partnerships with fertility networks in 2026—marking the U.S. commercial launch of the world’s first automated IVF lab.
Addressing Critical Industry Needs
The global fertility market faces significant challenges including rising demand (experts estimate unmet demand for IVF to be 10 times current numbers), limited clinic capacity, and cost barriers that affect accessibility. Conceivable tackles key challenges in the lab by boosting efficiency and bringing consistency to workflows, while improving success rates and reducing costs for patients.
“The fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care,” said Alex Christ, General Partner at Advance Venture Partners. “We saw a fragmented landscape of companies building low impact, point solutions for individual IVF processes, but only Conceivable tackling the full end-to-end approach to IVF that truly pushes the industry forward. By integrating these complex steps in one system, they’ve revolutionized the IVF lab with technology, engineering, and biology at the core. Conceivable’s technology will enable the entire sector to deliver fertility care that’s more consistent, scalable, and – most importantly – within reach for the families who need it most.”
